|
|
 |
|
Viewing report
|
|
|
|
European Head and Neck Cancer Therapeutics Markets
Frost & Sullivan, Aug 2007, Pages: 124
This Frost & Sullivan research service titled European Head and Neck Cancer Therapeutics Markets provides market drivers, restraints and revenue forecasts for this market. In this research, Frost & Sullivan's expert analysts thoroughly examine the chemotherapy and targeted therapies markets.
Targeted Therapy Improves Survival Rates among Patients with Head and Neck Cancer
Physicians in Europe are eager for novel therapies for head and neck cancer, as five-year survival rates among patients have remained low at 33.0 per cent for decades. Some of the new drugs that fall under targeted therapies have eliminated the shortcomings of traditional chemotherapy treatment by predominantly acting only on the cancer cells and leaving the healthy cells intact. These drugs achieve this precision by interfering with specific molecules involved in carcinogenesis and tumour growth. 'An example of targeted therapy is Erbitux (cetuximab), a first in class IgG1 monoclonal antibody (mAb), specifically targeting the epidermal growth factor receptor (EGFR),' says the analyst of this research service. 'mAbs are highly specific therapeutics and have improved side effects profiles.'
Most targeted therapies in the head and neck cancer segment are in clinical trials, as developers are hoping to test the viability of these therapies as stand-alone drugs as well as in combination with other therapies such as chemotherapy. Targeted therapy has scored over current treatments and is proving effective against a range of cancers including breast, colon, lung, kidney, head and neck and lymphoma.
Awareness Campaigns Required to Disseminate Information about Therapies for the Rarely-occurring Head and Neck Cancers
People have too little knowledge about head and neck cancers, as these are not as prevalent as other cancers. This insufficient information leads to delayed diagnosis and thus, late stage treatment, which greatly hampers pharmaceutical companies’ market growth. While later diagnosis could dramatically reduce the survival rate, earlier diagnosis could possibly mean a five-year survival rate of 70.0 to 90.0 per cent. Market participants need to target education and medical awareness programmes at the public and healthcare professionals, which work within multi-disciplinary teams, to promote early diagnosis.
Pharmaceutical companies also need to convince the public about the advantages of these prohibitively expensive products if they are to experience higher uptake. 'Until the benefits of the drugs have been clearly demonstrated in terms of overall cost savings and effectiveness, the use of this form of therapy is likely to remain restricted to very specific and wealthy patient populations,' notes the analyst. 'Biopharmaceutical and pharmaceutical companies should assess themselves and provide detailed and clear pharmacoeconomic analysis of these products so that mAbs become less restricted and reimbursement may be granted to additional patient groups.'
Customers who bought this item also bought
The Need for a European Contract Law
The European Convention and the Future of European Environmental Law
The Eastern European Cancer Market Outlook to 2010
European B2B Information Market 2006
The European Market for Organic Fruit & Vegetables
Legal Symbolism - On Law, Time and European Identity
European Market for Electronic Chemicals
European Osteoarthritis Markets
|
|
|
|
